Hear expert insights on risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults.
Learn about risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccine strategies for older adults.
There is a growing recognition of the effects of RSV among older adults, particularly those in long-term care facilities. Here’s my take on how preventing transmission can save millions in healthcare costs.
Vaccines are at the forefront of the national consciousness, and manufacturers of the highly effective COVID-19 vaccines have entered the race to find an effective RSV vaccine.
The potential availability of an effective RSV vaccine for older individuals is on the horizon, and with it comes numerous ways to address vaccine hesitancy in this patient population.
We are closer than ever to finding an effective RSV vaccine, but recent challenges may delay approval.
In this on-demand recording of a live webinar, expert faculty discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.